Nebulizers - Final LCD and Response to Comments (RTC) Article Published

Joint DME MAC Publication
Posted April 21, 2022

On April 21, 2022, the DME MACs published the following final Local Coverage Determination (LCD) and LCD-related Policy Article (PA):

  • Nebulizers LCD (L33370) and LCD-related PA (A52466)

The LCD incorporates finalized revisions, as a result of the LCD reconsideration request and written comments received during the comment period for the proposed LCD. The final Nebulizers LCD extends coverage to treprostinil inhalation solution used in the treatment of pulmonary hypertension (PH) associated with interstitial lung disease (ILD) and removes coverage of treprostinil inhalation solution and iloprost used in the treatment of chronic thromboembolic pulmonary hypertension (CTEPH).

The posting of the final LCD marks the beginning of the 45-day notice period. The final LCD goes into effect for claims with dates of service on or after June 5, 2022.

Along with the final LCD and LCD-related PA, the DME MACs published a Response to Comments (RTC) article, which address written comments received during the comment period. The RTC article is as follows:

  • Response to Comments: Nebulizers LCD - DL33370 (A59085)

Interested stakeholders may find the RTC document by searching for the article number in the Medicare Coverage Database. The RTC document is also located in the Associated Documents section of the LCD.

Please refer to each DME MAC website for additional information about policy development and access to the final LCD.

 

Last Updated Thu, 21 Apr 2022 12:30:01 +0000